Apollon Wealth Management’s NovoCure NVCR Stock Holding History

Apollon Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-125	Closed	-$7K	–	512
2020 Q2	$7K	Buy	+125	New	+$8.22K	﹤0.01%	531

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Apollon Wealth Management's NVCR Position: Q3 2020 in Review

Apollon Wealth Management sold out of NovoCure (NVCR) in Q3 2020, closing a stake of 125 shares — an estimated $7K sold.

Apollon Wealth Management first reported a position in NVCR in Q2 2020 and held it in 1 quarter. The position peaked at $7K in Q2 2020. 282 funds tracked by Wall St. Rank hold NVCR as of Q3 2020.

Apollon Wealth Management reported no remaining NovoCure position as of Q3 2020 after selling out during the quarter.
Apollon Wealth Management sold 125 NovoCure shares in Q3 2020, an estimated $7K.
Apollon Wealth Management first reported a position in NovoCure in Q2 2020 and held it in 1 quarter.
Apollon Wealth Management's NovoCure position peaked at $7K in Q2 2020.
282 funds tracked by Wall St. Rank held NovoCure as of Q3 2020.

Based on Apollon Wealth Management's 13F filing for Q3 2020, filed 3 Nov 2020.